Cofactor Genomics

Cofactor Genomics uses Predictive Immune Modeling for the development of faster, more cost effective and successful clinical trials. Predictive Immune Modeling acquires a picture of immune response at the tumor and represents the patient’s immune response, their response to therapy and potentially the prognosis, in a multi-faceted way. Multidimentional biomarkers help predict responses to drugs and therapy.

Cofactor Genomics analyzes the presence, absence of RNA and dynamic levels of gene expression. Genes that are expressed are active and transcribe RNA. Gene expression levels can be influenced by factors including the state of disease, environmental effects and therapy. Cofactor has built Health Expression Models, which are gene expression profiles for key immune cell types.

In February 2018, Cofactor announced a $100,000 grant program which will reward innovations that use the Cofactor ImmunoPrism Assay. CEO and founder Jarret Glasscock explains that the grant is designed to inspire researchers to take different approaches with the aim of achieving highly predictive biomarkers that can predict whether an immunotherapy will work with a specific patient or cancer type.

Solid tumor samples can be sent to Cofactor for analysis using the ImmunoPrism Assay and individual samples are compared to the Health Expression Models database which represents key immune cell types. An ImmunoPrism Report is generated for each patient. When clinical outcome data is available for patient cohorts, their Predictive Immune Modeling platform will generate a multidimensional biomarker. The platform uses machine-learning.

Cofactor provides a range of RNA sequencing services.

The ImmunoPrism (formerly called Paragon) assay completed validation and certification by the College of American Pathologists (CAP) in 2018. Cofactor’s ImmunoPrism Immune Profiling Kit was launched in 2018, which gives laboratories access to the same kit the company uses for sample preparation, sequencing and analysis of tumor samples.